Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Improving the Propranolol Treatment of Melanoma

Improving the Propranolol Treatment of Melanoma Letters increases her risk of ovarian cancer and possibly also her risk label study of which we are aware of propranolol for mela- 3 1 of triple-negative breast cancer. Absent comprehensive se- noma treatment. However, I would like to call attention to sev- quencing, this participant’s RAD51D nonsense mutation would eral points that need further clarification. Research has reported not have been detected. that propranolol inhibits melanoma growth in a U-shaped bi- With comprehensive sequencing, the greatest challenge phasic manner. Low propranolol doses lead to a significant to the field is not identifying mutations but interpreting them. melanoma growth inhibition, whereas higher doses are pro- Risks vary by gene and by cancer. For example, loss-of- gressively less effective. There is also evidence that proprano- function mutations in BRIP1 significantly increase risk of ovar- lol is metabolized via 4-hydroxylation by CYP2D6, a highly ian cancer, whereas effects on breast cancer risk are still polymorphic enzyme, and that CYP2D6 genetic polymor- 4 3 unclear. Mutations in NBN are proving to have at most mar- phism has a significant effect on its pharmacokinetics. Fur- ginal effect on either ovarian or breast cancer risk. We agree thermore, among the β-blockers, propranolol demonstrates a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Improving the Propranolol Treatment of Melanoma

Patanè, Salvatore
JAMA Oncology , Volume 4 (7) – Jul 10, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/improving-the-propranolol-treatment-of-melanoma-cyPCI0slbk

References (6)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.0598
Publisher site
See Article on Publisher Site

Abstract

Letters increases her risk of ovarian cancer and possibly also her risk label study of which we are aware of propranolol for mela- 3 1 of triple-negative breast cancer. Absent comprehensive se- noma treatment. However, I would like to call attention to sev- quencing, this participant’s RAD51D nonsense mutation would eral points that need further clarification. Research has reported not have been detected. that propranolol inhibits melanoma growth in a U-shaped bi- With comprehensive sequencing, the greatest challenge phasic manner. Low propranolol doses lead to a significant to the field is not identifying mutations but interpreting them. melanoma growth inhibition, whereas higher doses are pro- Risks vary by gene and by cancer. For example, loss-of- gressively less effective. There is also evidence that proprano- function mutations in BRIP1 significantly increase risk of ovar- lol is metabolized via 4-hydroxylation by CYP2D6, a highly ian cancer, whereas effects on breast cancer risk are still polymorphic enzyme, and that CYP2D6 genetic polymor- 4 3 unclear. Mutations in NBN are proving to have at most mar- phism has a significant effect on its pharmacokinetics. Fur- ginal effect on either ovarian or breast cancer risk. We agree thermore, among the β-blockers, propranolol demonstrates a

Journal

JAMA Oncology – American Medical Association

Published: Jul 10, 2018

There are no references for this article.